Poliomyelitis
📧 Sign up to get email alerts when something new happens for Poliomyelitis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-07EMA Authorised: Hexacima (hepatitis B surface antigen;Diphtheria toxoid;Bordetella pertussis antigens Pertussis Toxoid Filamentous Haemagglutinin;poliovirus (inactivated) type 1 (Mahoney) type 2 (MEF-1) type 3 (Saukett);Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) conjugated to Tetanus protein;tetanus toxoid) — Sanofi Winthrop Industrie
EMA authorised Hexacima, a combination vaccine covering hepatitis B, diphtheria, pertussis, poliomyelitis, Haemophilus influenzae type b, te…
-
EMA approval · 2026-08-07EMA Authorised: Hexyon (filamentous haemagglutinin;Haemophilus influenzae type B polysaccharide (polyribosylribitol phosphate);hepatitis B surface antigen;pertussis toxoid;poliovirus (inactivated) type 1 (Mahoney strain) produced on Vero cells;poliovirus (inactivated) type 2 (MEF-1 strain) produced on Vero cells;poliovirus (inactivated) type 3 (Saukett strain) produced on Vero cells;tetanus protein;tetanus toxoid adsorbed on aluminium hydroxide, hydrated;Diphtheria toxoid) — Sanofi Winthrop Industrie
EMA has authorised Hexyon, a combined immunization vaccine covering multiple diseases including hepatitis B, diphtheria, tetanus, pertussis,…
-
EMA approval · 2026-07-10EMA Authorised: Infanrix Hexa (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin);hepatitis B surface antigen;poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain));Haemophilus influenzae type b polysaccharide) — GlaxoSmithKline Biologicals S.A.
EMA has authorised Infanrix Hexa, a hexavalent vaccine by GlaxoSmithKline Biologicals S.A., covering multiple antigens including diphtheria,…
-
EMA approval · 2026-03-31EMA Authorised: Vaxelis (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae Types 2 and 3;hepatitis B surface antigen produced in yeast cells;poliovirus (inactivated): type 1 (Mahoney), type 2 (MEF-1), type 3 (Saukett) produced in Vero cells/ Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein.) — MCM Vaccine B.V.
The EMA has authorised Vaxelis, a combination vaccine containing diphtheria and tetanus toxoids, pertussis antigens, hepatitis B surface ant…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine [Phase 4]
A Phase IV clinical trial is evaluating sequential vaccination with Sabin-strain and wild-strain inactivated poliovirus vaccines for poliomy…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: The Impact of 'Digital Strolling' on Depression and Quality of Life of People With Severe Mobility Impairment [NA]
This completed study from The Hong Kong Polytechnic University evaluated whether a 'digital strolling' program affects depression and qualit…
-
EMA approval · 2026-02-12EMA Authorised: Infanrix Hexa (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin);hepatitis B surface antigen;poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain));Haemophilus influenzae type b polysaccharide) — GlaxoSmithKline Biologicals S.A.
The European Medicines Agency authorised Infanrix Hexa, a hexavalent vaccine that combines diphtheria, tetanus, pertussis, hepatitis B, poli…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations [Phase 4]
A Phase IV clinical study investigating sIPV administration in adolescent and adult populations is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: Booster Dose of sIPV Co-administered With MMR and HepA-I. [Phase 4]
Phase 4 booster-dose trial evaluating co-administration of sIPV with MMR and HepA-I has completed.
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
This clinical trial update examines five-year antibody persistence after vaccination with IPV, MMR, and HepA-L vaccines. The study is not ye…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation [Phase 2]
Phase 2 clinical trial update evaluating the co-administration of Novel Oral Poliomyelitis Vaccines Type 1 and Type 2 is currently recruitin…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh [Phase 2]
A Phase 2 clinical trial update for a novel Type 1 oral poliovirus vaccine being investigated in Bangladesh; study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-22Clinical Trial Update: Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell) [Phase 3]
Phase 3 trial of Sabin strain inactivated poliovirus vaccine (Vero cell) for poliomyelitis has completed.
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine [Phase 3]
A multi-center, open-label, randomized, controlled Phase 3 trial evaluating the sIPV vaccine for poliomyelitis has been completed.
-
EMA approval · 2025-09-29EMA Authorised: Hexyon (filamentous haemagglutinin;Haemophilus influenzae type B polysaccharide (polyribosylribitol phosphate);hepatitis B surface antigen;pertussis toxoid;poliovirus (inactivated) type 1 (Mahoney strain) produced on Vero cells;poliovirus (inactivated) type 2 (MEF-1 strain) produced on Vero cells;poliovirus (inactivated) type 3 (Saukett strain) produced on Vero cells;tetanus protein;tetanus toxoid adsorbed on aluminium hydroxide, hydrated;Diphtheria toxoid) — Sanofi Winthrop Industrie
EMA authorised Hexyon, a hexavalent vaccine combining protection against hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae…
-
EMA approval · 2025-09-29EMA Authorised: Hexacima (hepatitis B surface antigen;Diphtheria toxoid;Bordetella pertussis antigens Pertussis Toxoid Filamentous Haemagglutinin;poliovirus (inactivated) type 1 (Mahoney) type 2 (MEF-1) type 3 (Saukett);Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) conjugated to Tetanus protein;tetanus toxoid) — Sanofi Winthrop Industrie
The European Medicines Agency authorised Hexacima, a hexavalent vaccine combining hepatitis B surface antigen, diphtheria toxoid, pertussis …
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand [Phase 3]
Phase 3 study evaluating the DTwP-HepB-Hib-IPV (SHAN6) vaccine administered with routine vaccines in healthy infants and toddlers in Thailan…
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa [Phase 4]
This Phase 4 clinical trial assesses immune responses after a booster vaccination with Tdap-IPV in children who previously received differen…
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners [NA]
A clinical trial evaluating high-intensity functional training for individuals with neurologic conditions and their care partners has comple…
-
CLINICAL_TRIALS research · 2025-07-24Clinical Trial Update: A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants [Phase 3]
A Phase 3 clinical trial is evaluating mucosal immunity to poliovirus type-2 after birth-dose nOPV2 in healthy IPV-vaccinated infants; the s…
-
CLINICAL_TRIALS research · 2025-07-04Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers [Phase 1, Phase 2]
A Phase 1/2 study evaluating the safety and immunogenicity of a virus-like particle polio vaccine in infants and toddlers is currently recru…
-
CLINICAL_TRIALS research · 2025-07-03Clinical Trial Update: A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series [Phase 2, Phase 3]
Phase II/III trial update evaluating the immunogenicity, safety, and lot-to-lot consistency of LBVD, a fully liquid hexavalent DTaP-HepB-IPV…
-
CLINICAL_TRIALS research · 2025-06-03Clinical Trial Update: Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines [Phase 1, Phase 2]
The document reports a Phase 1/2 clinical trial evaluating trivalent and bivalent novel oral poliomyelitis vaccines, with recruitment curren…
-
CLINICAL_TRIALS research · 2025-05-01Clinical Trial Update: Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis [NA]
This clinical trial update compares functional outcomes between a micro-processor controlled orthosis and a stance-control orthosis in indiv…
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: Study of Concomitant Administration of the sIPV and DTaP or MMR [Phase 4]
Phase 4 trial evaluating concomitant administration of Sabin inactivated polio vaccine (sIPV) with DTaP or MMR vaccines; sponsored by the In…